Mylan Wants Supreme Court To Limit Patent Litigation Venue
Executive Summary
Federal Circuit decision permits brand-name drug makers to file infringement suits against generic manufacturers in whatever jurisdiction they wish.
You may also be interested in...
Supreme Court And Patents: What’s Not Happening
High court denies petition by Mylan to limit patent litigation venue and petition by Merck KGAA to address whether “on sale” bar to obtaining patent applies to non-public sales; Zarxio case to go to conference Friday.
Have Patent, Will Travel: Brand Firms Can File Infringement Suits Anywhere
Federal Circuit denies Mylan's bid to dismiss litigation in Delaware; PhRMA, BIO and Teva argued that brand manufacturers should be allowed to sue multiple generic manufacturers in a single forum.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.